Compare REX AI Equity Premium Income ETF (AIPI) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Amphastar Pharmaceuticals Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.29, while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AIPI | AMPH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $30.81 |
52-Week Low | $32.45 | $16.87 |
Market Cap | — | $863.95M |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.34, up 1.52% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock pays high weekly dividends, recently transitioning to this frequency to attract income investors. Key resistance lies at $38, with support at $36.
Outlook is mixed: high dividend yields near 35% offer income appeal, but sustainability concerns and structural risks from option-writing strategies pose challenges. Investors should weigh income benefits against potential NAV erosion if AI market momentum slows.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
